- Stocks
- Pharma & Healthcare
- Astonea Labs
Astonea Labs share price
NSE: ASTONEALABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Astonea Labs at a glance
With a market capitalisation of ₹281 Cr, it ranks 2097th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 29.1% in FY25. In Q3 FY25, the quarter ended 31 Dec 2024, revenue was ₹22 Cr and net profit ₹2 Cr, on a standalone basis. Promoters held 72.30% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹281 CrRank 2097 on NSE
- Price to book
- 0×FY25
- ROE
- 29.1%FY25
- ROCE
- 26.5%FY25
- Debt to equity
- 2.9FY25
- Net profit margin
- 5.5%FY25
- Book value / share
- ₹23.85FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Astonea Labs quarterly results
| Quarter | Q3 FY25 |
|---|---|
| Revenue | ₹22 Cr |
| Revenue YoY | — |
| Net profit | ₹2 Cr |
| Net profit YoY | — |
| Net margin | 8.8% |
| EPS | ₹2.55 |
Astonea Labs financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹30 Cr | ₹67 Cr | ₹80 Cr | ₹98 Cr |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹7 Cr |
| Net profit | ₹0 Cr | ₹1 Cr | ₹4 Cr | ₹5 Cr |
| EPS (₹) | ₹0.33 | ₹0.88 | ₹5.01 | ₹6.94 |
| Cash from operations | −₹5 Cr | −₹1 Cr | ₹4 Cr | ₹9 Cr |
| Total debt | ₹22 Cr | ₹19 Cr | ₹20 Cr | ₹22 Cr |
| Shareholders' equity | ₹7 Cr | ₹8 Cr | ₹12 Cr | ₹18 Cr |
Astonea Labs shareholding pattern
| Holder | 6 Jun 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|
| Promoters | 72.30% | 72.30% | 72.30% |
| Foreign institutions | 8.01% | 2.51% | 0.00% |
| Domestic institutions | 4.55% | 0.35% | 0.07% |
| Non-institutions | 15.14% | 24.83% | 27.63% |
Astonea Labs vs peers
The listed Pharma & Healthcare companies nearest to Astonea Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AMBALALSAAmbalal Sarabhai Enterprises | ₹38.95 | +3.18% | — | ₹298 Cr | 16.8 | — |
| BIJHANSBijoy Hans | — | — | — | ₹292 Cr | — | — |
| ASTONEALABAstonea Labs | — | — | — | ₹281 Cr | — | — |
| ESPIREEspire Hospital | — | — | — | ₹274 Cr | — | — |
| ZENOTECHZenotech Labs | — | — | — | ₹270 Cr | — | — |
| EVERESTOEverest Organic | — | — | — | ₹262 Cr | — | — |
| NATHBIOGENNath Bio-Genes (India) | ₹135.01 | −4.24% | −24.1% | ₹257 Cr | 6.4 | — |
Ask anything about Astonea Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against ASTONEALAB's own history. Try: “Why has ASTONEALAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on ASTONEALAB over five years” · “Compare ASTONEALAB with AMBALALSA on margins and valuation”
Frequently asked questions about Astonea Labs
What is the market cap of Astonea Labs?
Astonea Labs' market capitalisation is ₹281 Cr (₹281 Cr) at the 19 Oct 2026 close, ranking 2097th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Astonea Labs?
Return on equity was 29.1% in FY25 and return on capital employed was 26.5% in FY25 (standalone figures).
Is Astonea Labs a debt-free company?
No. Astonea Labs' debt-to-equity ratio was 2.9 in FY25, with total debt of ₹22 Cr.
What were Astonea Labs' latest quarterly results?
For Q3 FY25 (quarter ended 31 Dec 2024), Astonea Labs reported revenue of ₹22 Cr and net profit of ₹2 Cr.
What is the shareholding pattern of Astonea Labs?
As of 31 Mar 2026: promoters 72.30%, foreign institutions 0.00%, domestic institutions 0.07%, non-institutions 27.63%.
Who are Astonea Labs' competitors?
The listed Pharma & Healthcare companies closest to Astonea Labs by market cap are Ambalal Sarabhai Enterprises, Bijoy Hans, Espire Hospital, Zenotech Labs, Everest Organic and Nath Bio-Genes (India).
Is Astonea Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Astonea Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTONEALAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text